The biotech firm said it's had talks with large pharmaceutical companies for a possible partnership to expand commercialization efforts for its Qsymia obesity-fighting drug. That boosted Vivus (VVUS) shares 9.7% to 13.21. The company said Q1 Qsymia sales doubled to $4.1 mil, but missed analyst targets to for $5.2 mil. Its loss widened to 53 cents per share, from a 20-cents per-share loss a year ago. Analysts expected a 51-cent loss.
- Health Care Industry
- pharmaceutical companies